Tianjin Ringpu Bio Tech (300119) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Tianjin Ringpu Bio Tech (300119) has a cash flow conversion efficiency ratio of 0.020x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥105.02 Million ≈ $15.37 Million USD) by net assets (CN¥5.15 Billion ≈ $753.61 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See net asset quality index of Tianjin Ringpu Bio Tech to measure how much of total assets are equity-financed.
Tianjin Ringpu Bio Tech - Cash Flow Conversion Efficiency Trend (2007–2025)
This chart illustrates how Tianjin Ringpu Bio Tech's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check how high is Tianjin Ringpu Bio Tech's earnings quality to evaluate the quality of earnings relative to operating cash generation.
Tianjin Ringpu Bio Tech Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Tianjin Ringpu Bio Tech ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
MRC Global Inc
NYSE:MRC
|
-0.070x |
|
TF Bank AB
ST:TFBANK
|
-0.024x |
|
Azenta Inc
NASDAQ:AZTA
|
0.008x |
|
NINGBO HENGSHUAI Co. LTD.
SHE:300969
|
0.042x |
|
Bingo Software Co Ltd
SHG:688227
|
-0.028x |
|
Shenzhen Hello Tech Energy Co. Ltd. A
SHE:301327
|
N/A |
|
Iradimed Co
NASDAQ:IRMD
|
0.084x |
|
Asia Optical Co Inc
TW:3019
|
0.009x |
Annual Cash Flow Conversion Efficiency for Tianjin Ringpu Bio Tech (2007–2025)
The table below shows the annual cash flow conversion efficiency of Tianjin Ringpu Bio Tech from 2007 to 2025. For the full company profile with market capitalisation and key ratios, see Tianjin Ringpu Bio Tech market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | CN¥5.18 Billion ≈ $758.67 Million |
CN¥297.53 Million ≈ $43.54 Million |
0.057x | -60.94% |
| 2024-12-31 | CN¥5.01 Billion ≈ $732.68 Million |
CN¥735.55 Million ≈ $107.63 Million |
0.147x | +86.64% |
| 2023-12-31 | CN¥4.80 Billion ≈ $703.11 Million |
CN¥378.20 Million ≈ $55.34 Million |
0.079x | -9.04% |
| 2022-12-31 | CN¥4.50 Billion ≈ $658.65 Million |
CN¥389.49 Million ≈ $56.99 Million |
0.087x | -2.22% |
| 2021-12-31 | CN¥4.32 Billion ≈ $632.69 Million |
CN¥382.63 Million ≈ $55.99 Million |
0.088x | -37.64% |
| 2020-12-31 | CN¥2.74 Billion ≈ $400.51 Million |
CN¥388.44 Million ≈ $56.84 Million |
0.142x | -12.80% |
| 2019-12-31 | CN¥2.36 Billion ≈ $344.92 Million |
CN¥383.61 Million ≈ $56.13 Million |
0.163x | +109.80% |
| 2018-12-31 | CN¥2.25 Billion ≈ $329.89 Million |
CN¥174.88 Million ≈ $25.59 Million |
0.078x | +56.93% |
| 2017-12-31 | CN¥2.18 Billion ≈ $318.46 Million |
CN¥107.57 Million ≈ $15.74 Million |
0.049x | -49.89% |
| 2016-12-31 | CN¥2.11 Billion ≈ $308.09 Million |
CN¥207.67 Million ≈ $30.39 Million |
0.099x | -22.55% |
| 2015-12-31 | CN¥1.77 Billion ≈ $258.84 Million |
CN¥225.27 Million ≈ $32.96 Million |
0.127x | +71.20% |
| 2014-12-31 | CN¥1.73 Billion ≈ $252.53 Million |
CN¥128.37 Million ≈ $18.78 Million |
0.074x | +44.29% |
| 2013-12-31 | CN¥1.72 Billion ≈ $251.73 Million |
CN¥88.68 Million ≈ $12.98 Million |
0.052x | -9.05% |
| 2012-12-31 | CN¥1.59 Billion ≈ $232.13 Million |
CN¥89.92 Million ≈ $13.16 Million |
0.057x | -6.07% |
| 2011-12-31 | CN¥1.50 Billion ≈ $218.92 Million |
CN¥90.29 Million ≈ $13.21 Million |
0.060x | -23.68% |
| 2010-12-31 | CN¥1.43 Billion ≈ $208.78 Million |
CN¥112.82 Million ≈ $16.51 Million |
0.079x | -69.09% |
| 2009-12-31 | CN¥252.48 Million ≈ $36.95 Million |
CN¥64.59 Million ≈ $9.45 Million |
0.256x | -6.06% |
| 2008-12-31 | CN¥249.97 Million ≈ $36.58 Million |
CN¥68.07 Million ≈ $9.96 Million |
0.272x | +93.74% |
| 2007-12-31 | CN¥136.21 Million ≈ $19.93 Million |
CN¥19.15 Million ≈ $2.80 Million |
0.141x | -- |
About Tianjin Ringpu Bio Tech
Tianjin Ringpu Bio-Technology Co.,Ltd. engages in the research and development, production, and sale of veterinary raw materials, pharmaceutical preparation, functional additives, and veterinary biological products. The company provides vaccines, chemical drugs, traditional Chinese medicines; feed additives, including pigs, chickens, waterfowl, cattle, sheep and pet medicines, and vaccines; and p… Read more